Healthcare / Pharmaceutical RetailersBSE
$490.90
+23.35 (+4.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $12.0M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.6B
P/E
19.5x
↓EV/EBITDA
35.9x
↑ROE
25.7%
↑Gross Margin
36.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+189.2%
FCF CAGR
—
FCF margin
9.8%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.47B · net income $184.7M · FCF $143.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.47B | $1.47B | $630.1M | $181.2M | $60.8M |
| Net Income | $184.7M | $184.7M | $71.1M | $13.8M | $10.5M |
| EBITDA | $259.5M | $259.5M | $97.3M | $16.5M | $13.7M |
| EPS | 9.45 | 9.45 | 10.01 | 1.94 | 1.48 |
| Gross Margin | 36.1% | 36.1% | 22.8% | 23.4% | 32.1% |
| Operating Margin | 16.1% | 16.1% | 15.1% | 7.5% | 17.0% |
| Net Margin | 12.6% | 12.6% | 11.3% | 7.6% | 17.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.02 | 0.05 | 0.06 |
| Cash Flow | |||||
| Free Cash Flow | $143.4M | $143.4M | $12.0M | $-220000.00 | $-231000.00 |
| Returns | |||||
| ROE | 25.7% | 25.7% | 49.4% | 18.9% | 17.7% |
| Valuation | |||||
| P/E | 19.52 | 19.52 | 7.35 | 17.12 | 26.99 |
| EV/EBITDA | 35.94 | 35.94 | 5.28 | 14.47 | 20.86 |
| P/B | 13.38 | 13.38 | 3.63 | 3.24 | 4.80 |
| Growth & Yield | |||||
| Revenue Growth | 133.4% | 133.4% | 247.8% | 197.9% | — |
| EPS Growth | -5.6% | -5.6% | 416.0% | 31.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
66.4%
EPS terminal req.
$43.56
Spread vs growth
-72.0%
5Y implied EPS CAGR
41.0%
EPS terminal req.
$52.71
Spread vs growth
-46.6%
10Y implied EPS CAGR
24.5%
EPS terminal req.
$84.88
Spread vs growth
-30.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+95.9%
Start / end P/E
25.0x → 51.9x
EPS bridge
10.01 → 9.45
Residual
-6.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.